Auckland, NZ (PRWEB) September 01, 2013
Dr Richard Teague, spokesperson for Regenex Laboratories, says they have discovered how to use selected proteins within an ovine placenta extract base and combine it with peptides and signaling molecules designed to ‘wake up’ dormant stem cells in the body.
"Peptides are considered the future of medicine," he said. "And with this technology, using fractionated OVP in combination with peptides, we can provide an answer to HIV by reactivating the patient’s immune system."
"Up until now these products have only used in the controversial anti-ageing field, but now we have evidence that they actually do re-activate a person's stem cells. The stem cells are intelligent in that they seek out the area of most need in the body and repair it."
Dr Teague says the injectable cannot eradicate HIV from the body but it could potentially end the disease, as it provides a healthy immune system so patients can handle normal infections."
More than 33 million people have been diagnosed with HIV worldwide.
If clinical trials are successful, one initial 12 week course followed by a single dose every 3-4 months could be effective enough to replace the multiple therapies they currently need.
The key to the Immune Booster IM product is the filtering process which is used in the production process. The company has been able to achieve a filtration of less than 50,000 Dalton units, meaning the 5mg dose can be safely injected intramuscular, rather than having to be done intravenously.
"We have spent several years developing the production process and this is cutting edge technology now available to consumers worldwide."
"With HIV you have 2 options. You either have to eliminate the virus infection from the body, or you have to provide the body a mechanism by which it can naturally fight off simple diseases which to a HIV sufferer can be fatal. Immune Booster IM does that by activating dormant stem cells."
Dr Teague says that while the product is readily available now for anti ageing, and other conditions such as Rheumatoid arthritis and crones disease, the product is yet to undergo trials for HIV.
"This particular study is going to take some time, but so far every test that we have put this product through has passed with flying colors, and we have enough initial human tests results to know we have something special here," he said.
Successful clinical trials would present a rare bright spot in the ongoing battle against HIV. In August this year, U.S. trials for a potential AIDS vaccine were called off after the National Institute of Allergy and Infectious Diseases found the treatment — HVTN 505 —statistically ineffective compared to a placebo. (A cure differs from a vaccine in that the former works on people who have already contracted the virus.)
Immune Booster IM will be marketed as a cure since early trials indicate it has the ability to completely reverse the AIDS potency in the body, by boosting T-Cell counts and decreasing viral load. This comes about by the body itself fighting off the disease, after being re-activated by the Immune Booster IM.